Latest Insights - page 7 | BiopharmaTrend

Tamarind Bio Raises $13.6M to Run 200+ AI and Simulation Models in a No-Code Platform for Bench Scientists

Tamarind Bio has secured $13.6 million in Series A financing led by Dimension Capital with participation from Y Combinator to expand its platform for coordinating and deploying AI models in …

Continue ›››

Turbine Raises $25M to Scale AI Digital Cell Models Into Immunology, Following AstraZeneca Collaboration

Turbine, London- and Budapest-based virtual biology company building AI-driven “digital cell” models, has closed a $25 million Series B round. It was led by Interactive Venture Partners, with participation from …

Continue ›››

Ultima Genomics Launches Faster DNA Sequencers with Higher Output

Almost exactly a year since releasing UG100, Ultima Genomics has launched a new line of DNA sequencing systems, the UG200 Series, together with updated Solaris 2.0 workflows.

Continue ›››

New AI-Native Biotechs: 2026 Watchlist

Just a few days ago, the FDA formally established a one-pivotal-trial default for drug approval, explicitly emphasizing mechanistic, real-world, and model-based “confirmative evidence” around that study. Under the updated framework, …

Continue ›››

Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline. The beginning of this year is already offering …

Continue ›››

Y Combinator Backs Yale Spinout Using Agentic AI to De-risk Clinical Trials

CellType, a Yale University spinout, has joined Y Combinator’s W26 batch with a platform that combines foundation models of human biology with AI agents designed to run end-to-end AI modeling …

Continue ›››

FDA Shifts Drug Approval Policy: What Does This Mean for AI-Enabled Therapies?

The US Food and Drug Administration has formally shifted its evidentiary baseline for new drug applications, stating that one well-controlled clinical trial will now serve as the default requirement for …

Continue ›››

UK’s ARIA Backs Deep Origin & Arctoris Autonomous Scientist Initiative for Endometriosis

Deep Origin, in partnership with Arctoris, has been selected for the Advanced Research + Invention Agency’s AI Scientist program (ARIA), one of the UK’s most selective innovation initiatives. The joint …

Continue ›››

New Neurodegenerative Disease Biotech Launches With $175M to Test Brain-Penetrant Antibody for Alzheimer's

Korsana Biosciences has launched with $175 million in combined seed and Series A financing to develop brain-penetrant antibody therapies for neurodegenerative diseases. The company’s main investigational drug, KRSA-028, is an …

Continue ›››

Companies Applying AI to De-Risk Clinical Trials: 2026 Watchlist

Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest …

Continue ›››

Scribe and Eli Lilly Reach Second Milestone in In Vivo CRISPR Collaboration

Scribe Therapeutics reported a second milestone, achieved with the help of Scribe’s proprietary X-Editor (XE) platform, in its multi-program collaboration with Eli Lilly focused on in vivo CRISPR-based therapies for …

Continue ›››

Terray Updates its Binding-Affinity Predictor with Diffusion-Free AI Architecture

Terray Therapeutics, a Los Angeles–based biotechnology company developing an AI-driven small-molecule discovery platform, has introduced a new version of its TerraBind potency prediction model within the EMMI platform. The company …

Continue ›››